Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
公司代碼ALMR
公司名稱Alamar Biosciences Inc
上市日期Apr 17, 2026
CEOLuo (Yuling)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址47071 Bayside Pkwy
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94538
電話15106269888
網址https://alamarbio.com
公司代碼ALMR
上市日期Apr 17, 2026
CEOLuo (Yuling)